1Rochat B, Amey M, Gillet M, et al. Identification of three cytochrome P450 isozymes involved in N-demethylation of citalopram enantiomers in human liver microsomes[J]. Pharmacogenetics,7(1):l-10.
2Jiang T, Rong Z, Peng L, et al. Simultaneous determina- tion of citalopram and its metabolite in human plasma by LC-MS/MS applied to pharmacokinetic study [J]. J Chro- matogr B Analyt Technol Biomed Life Sci, 2010,878 (5- 6):615-619.
3Bies RR, Feng Y, Lotrich FE, et al.Utility of sparse con- centration sampling for citalopram in elderly clinical trial subjects[J]. J Clin Pharmacol, 2004,44(12): 1352-1359.
4Friberg LE, Isbister GK, Hackett LP, et al. The popula- tion pharmacokinetics of citalopram after deliberate self- poisoning: a Bayesian approach[J]. J Phalnacokinet Phar-macodyn, 2005,32(3-4):571-605.
5Yin OQ, Wing YK, Cheung Y, et al. Phenotype-genotype relationship and clinical effects of citalopram in Chinese patients [J]. J Clin Psychopharmacol, 2006, 26 (4): 367- 372.
6Joffe P, Larsen FS, Pedersen V, et al. Single-dose phar- macokinetics of citalopram in patients with moderate re- nal insufficiency or hepatic cirrhosis compared with healthy subjects [J]. Eur J Clin Pharmacol, 1998,54(3): 237-242.
7Spigset O, Hagg S, Stegmayr B, et al. Citalopram pharma- cokinetics in patients with chronic renal failure and the effect of haemodialysis[J]. Eur J Clin Pharrnacol, 2000,56 (9-10):699-703.
8Yu BN, Chen GL, He N, et al. Pharmacokinetics of citalopram in relation to genetic polymorphism of CYP2C19 [J]. Drug Metab Dispos, 2003,31 (10):1255- 1259.
9Pentikis HS, Henderson JD, Tran NL, et al. Bioequiva- lence: individual and population compartmental modeling compared to the noncompartmental approach [J]. Pharm Res, 1996,13(7): 1116-1121.
10Maier GA, Lockwood GF, Oppermann JA, et al. Charac- terization of the highly variable bioavailability of tilu- dronate in normal volunteers using population pharma- cokinetic methodologies [J]. Eur J Drug Metab Pharma- cokinet, 1999,24(3):249-254.
